Miháliková K, Ujházy E, Braxatorisová E, Kucera P
Institute of Preventive and Clinical Medicine, Bratislava, CSFR.
Toxicol In Vitro. 1993 Nov;7(6):803-7. doi: 10.1016/0887-2333(93)90084-i.
Stobadin (STO) is a prospective cardioprotective drug with antiarrhythmic and antihypoxic effects on the myocardium. Single iv injections of stobadin administered to rats on days 3, 6, 9 or 12 of gestation at doses of 2 and 6 mg/kg had no teratogenic effect. Slight foetal toxicity was manifested by decreased foetal weight (day 3 of gestation, 6 mg/kg) and increased incidence of delayed ossification of the skull (day 12 of gestation, 6 mg/kg). In vitro studies were performed on chick embryos explanted at Hamburger and Hamilton (HH) stages 4-5 and cultivated in a medium with stobadin concentration ranging from 10(-3) to 10(-8) mol/litre under standard conditions. Concentrations of 10(-3) and 10(-4) mol/litre were lethal. Embryos treated with concentrations from 10(-8) to 10(-5) mol/litre were comparable to those of the control group. The results of in vivo and in vitro tests showed that the antiarrhythmic agent stobadin at concentrations up to the maximal iv therapeutic dose had no overt effects on different developmental stages of the rat embryo and early chick embryogenesis.
斯托巴定（STO）是一种具有潜在心脏保护作用的药物，对心肌有抗心律失常和抗缺氧作用。在妊娠第3、6、9或12天，以2毫克/千克和6毫克/千克的剂量对大鼠单次静脉注射斯托巴定，未产生致畸作用。轻微的胎儿毒性表现为胎儿体重下降（妊娠第3天，6毫克/千克）和颅骨骨化延迟发生率增加（妊娠第12天，6毫克/千克）。对处于汉密尔顿和汉密尔顿（HH）第4 - 5阶段的鸡胚进行体外研究，并在标准条件下于含有浓度范围为10（-3）至10（-8）摩尔/升斯托巴定的培养基中培养。10（-3）和10（-4）摩尔/升的浓度具有致死性。用10（-8）至10（-5）摩尔/升浓度处理的胚胎与对照组相当。体内和体外试验结果表明，在达到最大静脉治疗剂量的浓度下，抗心律失常药物斯托巴定对大鼠胚胎和早期鸡胚发育的不同阶段没有明显影响。
